Ekso Bionics Holdings Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Ekso Bionics Holdings's earnings have been declining at an average annual rate of -1.9%, while the Medical Equipment industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 11.6% per year.
Información clave
-1.9%
Tasa de crecimiento de los beneficios
25.8%
Tasa de crecimiento del BPA
| Crecimiento de la industria Medical Equipment | 8.9% |
| Tasa de crecimiento de los ingresos | 11.6% |
| Rentabilidad financiera | -74.9% |
| Margen neto | -63.0% |
| Última actualización de beneficios | 30 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding
Aug 29
Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Jul 13Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00
May 02Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Dec 20Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Jun 19Ekso Bionics: Fragile Opportunity
Aug 24Is Ekso Bionics Holdings (NASDAQ:EKSO) A Risky Investment?
Jun 14Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?
Feb 05Ekso Bionics: Expecting More Of The Same
Jan 25Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?
Sep 22Ekso Bionics: Have Robot, Might Travel
Jul 09Shareholders May Not Be So Generous With Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) CEO Compensation And Here's Why
Jun 04Desglose de ingresos y gastos
Cómo gana y gasta dinero Ekso Bionics Holdings. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 24 | 18 | -11 | 17 | 4 |
| 30 Jun 24 | 18 | -12 | 17 | 4 |
| 31 Mar 24 | 18 | -14 | 18 | 4 |
| 31 Dec 23 | 18 | -15 | 20 | 4 |
| 30 Sep 23 | 17 | -15 | 20 | 4 |
| 30 Jun 23 | 16 | -16 | 21 | 4 |
| 31 Mar 23 | 14 | -15 | 20 | 3 |
| 31 Dec 22 | 13 | -15 | 19 | 3 |
| 30 Sep 22 | 13 | -15 | 20 | 3 |
| 30 Jun 22 | 13 | -12 | 19 | 3 |
| 31 Mar 22 | 12 | -11 | 19 | 2 |
| 31 Dec 21 | 11 | -10 | 19 | 2 |
| 30 Sep 21 | 9 | -11 | 16 | 2 |
| 30 Jun 21 | 9 | -6 | 15 | 2 |
| 31 Mar 21 | 9 | -17 | 15 | 2 |
| 31 Dec 20 | 9 | -16 | 16 | 2 |
| 30 Sep 20 | 10 | -15 | 16 | 2 |
| 30 Jun 20 | 11 | -17 | 17 | 2 |
| 31 Mar 20 | 12 | -8 | 19 | 3 |
| 31 Dec 19 | 14 | -12 | 19 | 4 |
| 30 Sep 19 | 13 | -14 | 22 | 5 |
| 30 Jun 19 | 13 | -21 | 22 | 5 |
| 31 Mar 19 | 12 | -26 | 24 | 5 |
| 31 Dec 18 | 11 | -27 | 26 | 5 |
| 30 Sep 18 | 10 | -32 | 26 | 6 |
| 30 Jun 18 | 10 | -31 | 27 | 7 |
| 31 Mar 18 | 8 | -29 | 26 | 8 |
| 31 Dec 17 | 7 | -29 | 24 | 9 |
| 30 Sep 17 | 7 | -26 | 22 | 9 |
| 30 Jun 17 | 7 | -31 | 22 | 10 |
| 31 Mar 17 | 7 | -35 | 22 | 9 |
| 31 Dec 16 | 14 | -34 | 21 | 8 |
| 30 Sep 16 | 14 | -38 | 21 | 8 |
| 30 Jun 16 | 15 | -31 | 19 | 8 |
| 31 Mar 16 | 15 | -27 | 18 | 7 |
| 31 Dec 15 | 9 | -24 | 17 | 6 |
| 30 Sep 15 | 8 | -35 | 16 | 5 |
| 30 Jun 15 | 7 | -18 | 15 | 5 |
| 31 Mar 15 | 6 | 44 | 14 | 4 |
| 31 Dec 14 | 5 | -34 | 15 | 4 |
| 30 Sep 14 | 5 | -16 | 12 | 3 |
| 30 Jun 14 | 4 | -30 | 11 | 2 |
| 31 Mar 14 | 4 | -90 | 9 | 3 |
| 31 Dec 13 | 3 | -12 | 9 | 2 |
Ingresos de calidad: EKSO is currently unprofitable.
Margen de beneficios creciente: EKSO is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: EKSO is unprofitable, and losses have increased over the past 5 years at a rate of 1.9% per year.
Acelerando crecimiento: Unable to compare EKSO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: EKSO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).
Rentabilidad financiera
Alta ROE: EKSO has a negative Return on Equity (-74.86%), as it is currently unprofitable.